134 related articles for article (PubMed ID: 10197301)
1. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers.
Meadowcroft AM; Williamson KM; Patterson JH; Hinderliter AL; Pieper JA
J Clin Pharmacol; 1999 Apr; 39(4):418-24. PubMed ID: 10197301
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
Fischer TL; Pieper JA; Graff DW; Rodgers JE; Fischer JD; Parnell KJ; Goldstein JA; Greenwood R; Patterson JH
Clin Pharmacol Ther; 2002 Sep; 72(3):238-46. PubMed ID: 12235444
[TBL] [Abstract][Full Text] [Related]
4. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
Kaukonen KM; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703
[TBL] [Abstract][Full Text] [Related]
5. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
Transon C; Leemann T; Vogt N; Dayer P
Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
[TBL] [Abstract][Full Text] [Related]
6. The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan.
Kobayashi M; Takagi M; Fukumoto K; Kato R; Tanaka K; Ueno K
Drug Metab Pharmacokinet; 2008; 23(2):115-9. PubMed ID: 18445991
[TBL] [Abstract][Full Text] [Related]
7. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers.
Williamson KM; Patterson JH; McQueen RH; Adams KF; Pieper JA
Clin Pharmacol Ther; 1998 Mar; 63(3):316-23. PubMed ID: 9542475
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Transon C; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
[TBL] [Abstract][Full Text] [Related]
9. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
Stearns RA; Chakravarty PK; Chen R; Chiu SH
Drug Metab Dispos; 1995 Feb; 23(2):207-15. PubMed ID: 7736913
[TBL] [Abstract][Full Text] [Related]
13. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.
Kim MJ; Nafziger AN; Kashuba AD; Kirchheiner J; Bauer S; Gaedigk A; Bertino JS
Eur J Clin Pharmacol; 2006 Jun; 62(6):431-6. PubMed ID: 16758259
[TBL] [Abstract][Full Text] [Related]
14. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.
Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH
Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036
[TBL] [Abstract][Full Text] [Related]
15. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.
Zaidenstein R; Soback S; Gips M; Avni B; Dishi V; Weissgarten Y; Golik A; Scapa E
Ther Drug Monit; 2001 Aug; 23(4):369-73. PubMed ID: 11477318
[TBL] [Abstract][Full Text] [Related]
16. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
17. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
Damkier P; Hansen LL; Brosen K
Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.
Buzková H; Pechandová K; Danzig V; Vareka T; Perlik F; Zak A; Slanar O
Med Sci Monit; 2012 Aug; 18(8):CR512-517. PubMed ID: 22847201
[TBL] [Abstract][Full Text] [Related]
19. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
Choi DH; Li C; Choi JS
J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879
[TBL] [Abstract][Full Text] [Related]
20. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.
Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]